BLUENERGIES LTD (BLU.CA) Stock Price & Overview
TSX:BLU • CA0959221007
Current stock price
The current stock price of BLU.CA is 2.1 CAD. Today BLU.CA is up by 3.45%. In the past month the price increased by 28.93%.
BLU.CA Key Statistics
- Market Cap
- 266.278M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
BLU.CA Stock Performance
BLU.CA Stock Chart
BLU.CA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to BLU.CA.
BLU.CA Earnings
BLU.CA Forecast & Estimates
BLU.CA Groups
Sector & Classification
BLU.CA Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BLU.CA Ownership
BLU.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 562.152M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 418.361M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 140.539M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 51.72M | ||
| COV | COVALON TECHNOLOGIES LTD | 11.93 | 47.506M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 39.005M | ||
| RVX | RESVERLOGIX CORP | N/A | 36.331M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 3.25 | 32.559M | ||
| HEM | HEMOSTEMIX INC | N/A | 13.668M | ||
| MPH | MEDICURE INC | N/A | 11.693M | ||
| KNE | KANE BIOTECH INC | N/A | 6.356M | ||
| QPT | QUEST PHARMATECH INC | N/A | 5.074M | ||
| TELO | TELO GENOMICS CORP | N/A | 4.519M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About BLU.CA
Company Profile
BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. The company is headquartered in Laval, Quebec and currently employs 74 full-time employees. The company went IPO on 2000-06-22. The firm's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The firm has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The firm is focused on initiating Phase III program. The firm is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.
Company Info
IPO: 2000-06-22
BLUENERGIES LTD
275 Armand-Frappier Blvd
Laval QUEBEC H7V 4A7 CA
CEO: Roberto Bellini
Employees: 74
Phone: 14506804500.0
BLUENERGIES LTD / BLU.CA FAQ
Can you describe the business of BLUENERGIES LTD?
BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. The company is headquartered in Laval, Quebec and currently employs 74 full-time employees. The company went IPO on 2000-06-22. The firm's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The firm has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The firm is focused on initiating Phase III program. The firm is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.
What is the stock price of BLUENERGIES LTD today?
The current stock price of BLU.CA is 2.1 CAD. The price increased by 3.45% in the last trading session.
What is the dividend status of BLUENERGIES LTD?
BLU.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of BLU stock?
BLU.CA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the market capitalization of BLU stock?
BLUENERGIES LTD (BLU.CA) has a market capitalization of 266.28M CAD. This makes BLU.CA a Micro Cap stock.